255 related articles for article (PubMed ID: 23263867)
1. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease.
Harward LE; Mitchell K; Pieper C; Copland S; Criscione-Schreiber LG; Clowse ME
Lupus; 2013 Jan; 22(1):81-6. PubMed ID: 23263867
[TBL] [Abstract][Full Text] [Related]
2. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
Somers EC; Marder W; Christman GM; Ognenovski V; McCune WJ
Arthritis Rheum; 2005 Sep; 52(9):2761-7. PubMed ID: 16142702
[TBL] [Abstract][Full Text] [Related]
3. Fertility, ovarian failure, and pregnancy outcome in SLE patients treated with intravenous cyclophosphamide in Saudi Arabia.
Alarfaj AS; Khalil N
Clin Rheumatol; 2014 Dec; 33(12):1731-6. PubMed ID: 24894105
[TBL] [Abstract][Full Text] [Related]
4. Effect of a gonadotropin-releasing hormone analog for ovarian function preservation after intravenous cyclophosphamide therapy in systemic lupus erythematosus patients: a retrospective inception cohort study.
Koga T; Umeda M; Endo Y; Ishida M; Fujita Y; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Fukui S; Nishino A; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Murakami N; Kitajima M; Kawakami A
Int J Rheum Dis; 2018 Jun; 21(6):1287-1292. PubMed ID: 29879312
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.
Marder W; McCune WJ; Wang L; Wing JJ; Fisseha S; McConnell DS; Christman GM; Somers EC
Gynecol Endocrinol; 2012 Aug; 28(8):624-7. PubMed ID: 22296584
[TBL] [Abstract][Full Text] [Related]
6. Fertility preservation in women with vasculitis: experiences from the FertiPROTEKT network.
Henes JC; Henes M; von Wolff M; Schmalzing M; Kötter I; Lawrenz B
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S53-6. PubMed ID: 22512886
[TBL] [Abstract][Full Text] [Related]
7. Prevention of gonadal toxicity and preservation of gonadal function and fertility in young women with systemic lupus erythematosus treated by cyclophosphamide: the PREGO-Study.
Manger K; Wildt L; Kalden JR; Manger B
Autoimmun Rev; 2006 Apr; 5(4):269-72. PubMed ID: 16697968
[TBL] [Abstract][Full Text] [Related]
8. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil.
Laskari K; Zintzaras E; Tzioufas AG
Clin Exp Rheumatol; 2010; 28(1):83-6. PubMed ID: 20346244
[TBL] [Abstract][Full Text] [Related]
9. [Cyclophosphamide induced amenorrhoea in pre-menopausal women with systemic lupus erythematosus].
Cunha I; Saavedra MJ; Pereira da Silva JA; Malcata A
Acta Reumatol Port; 2008; 33(1):69-76. PubMed ID: 18344924
[TBL] [Abstract][Full Text] [Related]
10. Fertility counseling and preservation practices in youth with lupus and vasculitis undergoing gonadotoxic therapy.
Nahata L; Sivaraman V; Quinn GP
Fertil Steril; 2016 Nov; 106(6):1470-1474. PubMed ID: 27521770
[TBL] [Abstract][Full Text] [Related]
11. Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network.
Henes M; Henes JC; Neunhoeffer E; Von Wolff M; Schmalzing M; Kötter I; Lawrenz B
Lupus; 2012 Aug; 21(9):953-8. PubMed ID: 22438026
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.
Mok CC; Lau CS; Wong RW
Arthritis Rheum; 1998 May; 41(5):831-7. PubMed ID: 9588734
[TBL] [Abstract][Full Text] [Related]
13. Anti-müllerian hormone and ovarian reserve in systemic lupus erythematosus.
Mok CC; Chan PT; To CH
Arthritis Rheum; 2013 Jan; 65(1):206-10. PubMed ID: 23044647
[TBL] [Abstract][Full Text] [Related]
14. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients.
Huong DL; Amoura Z; Duhaut P; Sbai A; Costedoat N; Wechsler B; Piette JC
J Rheumatol; 2002 Dec; 29(12):2571-6. PubMed ID: 12465154
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases.
Blumenfeld Z; Mischari O; Schultz N; Boulman N; Balbir-Gurman A
Semin Arthritis Rheum; 2011 Dec; 41(3):346-52. PubMed ID: 21868068
[TBL] [Abstract][Full Text] [Related]
16. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy.
Sen M; Kurl A; Khosroshahi A
Lupus; 2021 Aug; 30(9):1509-1514. PubMed ID: 34053364
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
[TBL] [Abstract][Full Text] [Related]
19. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
Blumenfeld Z
Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy outcome in women with systemic lupus erythematosus treated with immunosuppressive drugs.
Ramsey-Goldman R; Mientus JM; Kutzer JE; Mulvihill JJ; Medsger TA
J Rheumatol; 1993 Jul; 20(7):1152-7. PubMed ID: 8371208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
